NCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
Clinical Trials
13 trialsNCT03601923 2026-01-28
Niraparib in Patients With Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT06747845 2025-09-16
ParpVax2
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT04409002 2025-08-15
Niraparib + Dostarlimab + RT in Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04493060 2025-08-07
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Completed
NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
NCT03840967 2024-06-04
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT05412706 2023-09-08
Bohème
Ospedale Policlinico San Martino
Phase 2 Withdrawn
NCT04895046 2022-06-29
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn